Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors

Pancreas

Volumn 40, Issue 8, 2011, Pages 1253-1257

  Curran, Thomas ^a   Tulin Silver, Sheryl ^a   Patel, Kalpesh ^a   Ward, Stephen ^b   Schneiderman, Melissa ^a   Harpaz, Noam ^b   Schwartz, Myron ^c   Itzkowitz, Steven ^a   Warner, Richard R P ^a   Kim, Michelle Kang ^a  

^a Division of Gastroenterology   (United States)

^b Department of Pathology ^*  (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

carcinoid; chromogranin; metastatic; neuroendocrine; small bowel; tumor

Indexed keywords

BIOLOGICAL MARKER; CHROMOGRANIN A; KI 67 ANTIGEN;

ADULT; AGE; AGED; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; METASTASIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SEX; SMALL INTESTINE TUMOR; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; CHROMOGRANIN A; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80054846628     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318225483c     Document Type: Conference Paper

References (30)

1. Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am. 2007;21(3):433-455, viiYviii.
2. Landry CS, Brock G, Scoggins CR, et al. A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery. 2008;144(3):460-466.
3. Landry CS, Brock G, Scoggins CR, et al. Proposed staging system for colon carcinoid tumors based on an analysis of 2,459 patients. J Am Coll Surg. 2008;207(6):874-881.
4. Landry CS, Brock G, Scoggins CR, et al. A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients. Am J Surg. 2008;196(6):896-903, discussion 903.
5. Modlin IM, Champaneria MC, Chan AK, et al. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: The rapid pace of no progress. Am J Gastroenterol. 2007;102(7):1464-1473.
6. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 2007;451(4):757-762.
7. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18): 3063-3072.
8. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-959.
9. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89(4):471-476.
10. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: Results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885-894.
11. Williams BC, Demitrack LB, Fries BE. The accuracy of the National Death Index when personal identifiers other than Social Security number are used. Am J Public Health. 1992;82(8):1145-1147.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
13. Oberg K. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors. Expert Rev Anticancer Ther. 2009;9(5):557-566.
14. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656- 4663.
15. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-1425.
16. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21(1):33-41.
17. Kolby L, Bernhardt P, Sward C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept. 2004;120(1-3):269-273.
18. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685-690.
19. Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009;89(3):302-307.
20. Jensen EH, Kvols L, McLoughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007;14(2):780-785.
21. Amarapurkar AD, Davies A, Ramage JK, et al. Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: Relevance to prognosis. Eur J Gastroenterol Hepatol. 2003;15(2):139-143.
22. Chaudhry A, Oberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol. 1992;13(1-2):27-35.
23. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med. 2000;44(1):13-21.
24. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29-37.
25. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572-581.
26. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134(6): 1057-1063, discussion 1063-1065.
27. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108(6):1091-1096.
28. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The M.D. Anderson experience. Cancer J. 2003;9(4):261-267.
29. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83(11):2293-2301.
30. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: The role of ablative techniques. Cardiovasc Intervent Radiol. 2005;28(4):409-421.